Introduction
Epithelial tissues which are chronically in®ltrated with in¯ammatory leukocytes have an increased incidence of developing malignant tumors (Weitzman and Gordon, 1990) . For instance, 10 ± 60% of patients with ulcerative colitis, a disease characterized by chronic in®ltration of the colon with leukocytes, eventually develop colon cancer (Devroede et al., 1971; Greenstein et al., 1979) . Similarly, chronic in¯ammation of the skin, urinary bladder, gall bladder, stomach, esophagus, bone, etc, is associated with an increased incidence of malignancies in these tissues (Weitzman and Gordon, 1990) . In addition to this well-known association between in¯ammation and human carcinogenesis, previous studies have also demonstrated that cultured mouse ®broblast cells can be transformed into malignant cells when exposed to in¯ammatory leukocytes (Weitzman et al., 1985; Nassi-Calo et al., 1989; Zimmerman and Cerutti, 1984) .
The mechanism by which leukocytes contribute to carcinogenesis is unknown. Previous studies have shown, however, that stimulated leukocytes can cause DNA damage; and it is possible that this DNA damage could contribute (at least in part) to carcinogenesis. Stimulated leukocytes release superoxide anion (O 2 7 ⋅ ) and hydrogen peroxide (H 2 O 2 ) (Babior, 1978) . Although neither of these oxygen metabolites appear to be directly toxic to DNA (Halliwell and Aruoma, 1991) , H 2 O 2 can diuse into target cells and react with iron (or other transition metals) that is either bound to or in close proximity to DNA (Schraufstatter et al., 1988; Halliwell, 1987 
OH (or a
OH-like species) can cause DNA strand breaks, DNA base modi®cations, sister chromatid exchanges, and mutations (Halliwell and Aruoma, 1991; Jackson et al., 1989; Weitberg et al., 1983; Weitzman and Stossel, 1982; Birnboim, 1982; Lewis and Adams, 1985; Schraufstatter et al., 1986a,b; Frenkel et al., 1986; Floyd et al., 1986) . However, despite the large body of evidence demonstrating the damaging eects of .
OH on DNA, it remains unknown to what (if any) degree
. OH-induced DNA damage contributes to carcinogenesis. Speci®cally, since, in addition to causing DNA damage, leukocyte-derived . OH also causes a number of other potentially carcinogenic eects (including non-speci®c stimulation of cell proliferation, activation of procarcinogens into carcinogens, conversion of endogenous compounds into genotoxic intermediates, etc. [Weitzman and Gordon, 1990] ), it has been dicult to ascertain whether leukocyte-derived . OH contributes to cell transformation through genetic (DNA damage) or epigenetic mechanisms. To circumvent this problem, we designed studies to directly and speci®cally test whether leukocyte-derived . OH-induced DNA damage can contribute to carcinogenesis.
Certain types of DNA damage can convert normal protooncogenes into activated oncogenes, and these activated oncogenes are believed to play a major role in human carcinogenesis. K-ras is the most frequent oncogene detected in human malignancies ± it is detected in approximately 50% of colon, 90% of pancreatic, and 30% of lung adenocarcinomas (Rodenhuis, 1992; Bos, 1989) . In light of the frequent activation of K-ras in human cancers, we determined whether leukocyte-derived . OH-induced DNA damage could cause K-ras oncogene activation. The studies reported herein demonstrate that leukocyte-derived . OH-induced DNA damage can cause K-ras oncogene activation, and begin to de®ne some of the possible characteristics of this activation.
Results
Transforming activity of leukocyte-or purine and xanthine oxidase-treated K-ras 4B plasmid DNA OHinduced DNA damage can cause K-ras oncogene activation, normal human K-ras 4B protooncogene plasmid DNA was treated with PMA-stimulated human neutrophils in the presence or absence of iron; and treated plasmid DNA was subsequently transfected into NIH3T3 cells to assess K-ras oncogene activation. As can be seen in Table 1 , approximately 32% of NIH3T3 cell dishes transfected with K-ras DNA treated with PMA-stimulated neutrophils and iron developed transformed foci. In contrast, dishes transfected with K-ras DNA treated with PMA or iron alone, did not develop transformed foci. For comparison, we also assessed whether neutrophil-derived . OH-induced DNA damage could cause H-ras oncogene activation. Interestingly, only one out of 4100 NIH3T3 cell dishes transfected with H-ras DNA treated with PMA-stimulated neutrophils and iron developed transformed foci.
To further support the role of .
OH in neutrophilinduced K-ras oncogene activation, we tested whether the enzymatic system, purine and xanthine oxidase, which generates O 2 7 ⋅ and H 2 O 2 , could also cause K-ras oncogene activation. As indicated in Table 1 , approximately 31% of NIH3T3 cell dishes transfected with purine and xanthine oxidase-treated K-ras DNA developed transformed foci. Dishes transfected with K-ras DNA treated with purine or xanthine oxidase alone did not develop transformed foci. (Note: Since our xanthine oxidase preparation was contaminated with a signi®cant amount of iron, it was not necessary to add exogenous iron to our DNA mixtures containing purine and xanthine oxidase. However, addition of the iron chelator, deferroxamine to DNA mixtures containing purine and xanthine oxidase completely prevented K-ras oncogene activation [data not shown]).
These combined results strongly suggest that . OH, generated from neutrophil-derived O 2 7 ⋅ and H 2 O 2 , causes DNA damage that converts the K-ras protooncogene into a transforming oncogene.
Characterization of K-ras mutations induced by leukocytes or purine and xanthine oxidase
To determine the speci®c K-ras mutations induced by neutrophil-or purine and xanthine oxidase-derived . OH, the transformed secondary foci indicated in Table 1 were subcloned, and DNA isolated from these subcloned foci was ampli®ed by the polymerase chain reaction (PCR) and directly sequenced. A summary of the speci®c K-ras mutations induced by neutrophil-or purine and xanthine oxidase-derived . OH is presented in Table 2 . There appeared to be several characteristics of . OHinduced K-ras oncogene activation: (1) G/C base pairs were mutated more frequently than A/T base pairs. Speci®cally, 20 out of the 25 total transitions/ transversions detected involved G/C base pairs. (2) there was signi®cant selectivity in the speci®c types of transitions/transversions detected. For instance, we only detected one G/C?C/G transversion in comparison to ®ve G/C?A/T transitions and six G/C?T/A transversions at codon 12. This apparent selectivity for certain transitions/transversions was not limited to codon 12, but appeared to be applicable to the entire K-ras coding sequence. Speci®cally, of the 20 G/C transitions/transversions detected, ten were G/C?T/A, eight were G/C?A/T and only two were G/C?C/G. (3) mutations were unequally distributed amongst a number of dierent codons. We detected 12 mutations at codon 12, ®ve mutations at codon 61, two mutations at codon 13 or 117, and only one mutation at codon 18, 58, 63, or 146.
Characterization of K-ras mutations induced by 8 hydroxydeoxyguanosine
Since the aforementioned studies clearly demonstrated that DNA damage induced by neutrophil-derived . K-ras 4B plasmid DNA (10 mg) was treated with PMA (250 ng/ml), human neutrophils (4610 6 /ml), purine (2 mM), xanthine oxidase (0.005 units/ml), and/or FeSO 4 /EDTA (10 mM/20 mM) for 1 h at 378C, and 1mg of treated K-ras DNA was subsequently transfected into NIH3T3 cells. Primary transformed foci which developed in transfected cells were subcloned; genomic DNA isolated from these transformants was individually re-transfected into NIH3T3 cells; and the number of dishes containing secondary transformed foci was assessed after 14 days. Data indicate the number of primary transfection dishes that contained foci whose DNA subsequently induced secondary transformants. All primary transfection dishes contained only one transformant 
OH
Genomic DNA isolated from the secondary transformants indicated in Table 1 (Jackson et al., 1989) . Accordingly, since the majority of K-ras mutations detected in human cancers involve transitions/transversions of deoxyguanosine at the ®rst or second position of codon 12 (Bos, 1989) , we assessed the ability of 8 hydroxydeoxyguanosine, sitespeci®cally substituted for either the ®rst or second base of K-ras codon 12 DNA sequence, to cause activating point mutations.
Similar to our ®ndings with leukocyte-treated K-ras DNA, there was signi®cant selectivity in the speci®c types of transitions/transversions detected in 8 hydroxydeoxyguanosine-containing DNA. Speci®cally, all of the mutants contained either G/C?T/A transversions or G/C?A/T transitions. No G/C?C/G transversions were detected. Interestingly, substitution of 8 hydroxydeoxyguanosine for deoxyguanosine at the second position of codon 12 caused more oncogenic Kras mutations than substitution of 8 hydroxydeoxyguanosine at the ®rst position of codon 12 (see Table  3 ). Moreover, 8 hydroxydeoxyguanosine incorporated at the second position of codon 12 caused mutations at both the ®rst and second positions of codon 12.
Expression of oncogenic K-Ras 4B proteins
In order to verify that morphologically transformed NIH3T3 cells containing . OH-activated K-ras oncogenes expressed mutant K-Ras 4B proteins, transformed cells were labeled with 35 S Met/Cys, and Ras proteins contained in these cells were immunoprecipitated and analysed by SDS ± PAGE and¯uorography. Figure 1 demonstrates that cells containing neutrophilderived . OH-activated K-ras oncogenes eciently expressed each of the mutant K-Ras 4B proteins. (Note: in order to selectively assess the expression of exogenous K-Ras 4B protein, we employed a K-ras 4B cDNA clone which contains a 10 amino acid Nterminal leader. Accordingly, endogenous Ras proteins have a faster electrophoretic mobility than exogenous K-Ras 4B protein, and are not visualized in the ®gure). Similar results were obtained for cells containing purine and xanthine oxidase-derived .
OH-activated Kras oncogenes (data not shown). Since previous studies have shown that point mutations can alter the electrophoretic mobility of Ras proteins (Srivastava et al., 1985) , the dierent electrophoretic mobilities of the oncogenic K-Ras 4B proteins in Figure 1 are likely a result of their dierent point mutations.
Discussion
Our results indicate that DNA damage induced by neutrophil-derived .
OH (or a
OH-like species) can cause K-ras oncogene activation. Since the activated K-ras oncogene is believed to contribute to the pathogenesis of many human malignancies, the ability of leukocyte-derived . OH-induced DNA damage to activate K-ras could explain, at least in part, the increased propensity of tissues which are chronically in®ltrated with leukocytes to develop malignancies.
Interestingly, although leukocyte-derived . OH caused very ecient K-ras oncogene activation, leukocyte-derived . OH was very inecient at causing H-ras oncogene activation, under identical experimental conditions. These results are consistent with the very infrequent activation of H-ras in human epithelial carcinomas in comparison to the frequent activation of K-ras in these malignancies (Rodenhuis, 1992) . We do not currently know why K-ras may be more susceptible to . OH-induced activation than H-ras. The transforming activity of activated H-ras or K-ras oncogenes in NIH3T3 cells is equivalent (Jackson et al., 1994) . In addition, a recent study (Kamiya et al., 1992) has A synthetic double-stranded oligonucleotide, encoding codons 9 ± 13 of K-ras 4B and containing 8 hydroxydeoxyguanosine substituted for deoxyguanosine at the ®rst or second position of codon 12, was ligated in frame into a vector containing codons 1 ± 8 and codons 14 ± 189 of a non-transforming v-H-ras cDNA clone. Reconstituted K-ras 4B/v-H-ras plasmid DNA (400 ng) was subsequently transfected into NIH3T3 cells; transformed foci which developed in transfected cells were subcloned; genomic DNA (20 mg) isolated from these subclones was re-transfected into NIH3T3 cells; and DNA isolated from secondary transformants was ampli®ed by the polymerase chain reaction and directly sequenced. a 8 hydroxydeoxyguanosine (G*) incorporated into the ®rst position of codon 12. OH attack. Our observed dierences between K-ras and H-ras emphasize the importance of using genes that are relevant to human carcinogenesis in studies aimed at determining the potential mutational activity of a given carcinogen.
It is generally believed that the vast majority of Kras mutations in human cancers occur at codon 12 (Bos, 1989) . Although codon 12 was the most frequent site of K-ras mutations in our studies (12/25 mutations), we also detected a signi®cant number of mutations at codon 61 (5/25) and one or two mutations at codons 13, 18, 58, 63, 117, and 146. While our results dier from what has been most often found in human cancers, many of the studies evaluating human cancers for evidence of K-ras activation have limited their focus to codon 12 and/ or used insensitive detection methods. Notably, however, one study (Suzuki et al., 1990) , which used a very sensitive technique (single-strand conformational polymorphism of PCR products) to analyse 14 human lung adenocarcinomas, detected a signi®cant number of K-ras mutations at codons 61 (3/14) and 13 (4/14), as well as codon 12 (6/14). Moreover, one of the 14 lung adenocarcinomas contained the identical codon 18 mutation we detected in our .
OH-treated K-ras DNA. In addition, the identical codon 146 mutation we detected has been found in human colon cancers (Orita et al., 1991) , and in vitro mutagenesis of cloned normal H-, N-, or K-ras genes has demonstrated that mutations at codon 12, 13, 59, 61, 63, 116, 117, 119, or 146 can all convert ras into an eciently transforming oncogene (Barbacid, 1987) . Furthermore, we have found that the novel codon 18 mutation detected in our studies also activates K-ras transforming activity (JH Jackson et al., unpublished results) . Although the number of . OH-induced K-ras mutations analysed in the present study is insucient to draw any statistically signi®cant conclusions about the site(s) of . OH-induced K-ras mutations; our results, combined with the aforementioned studies, raise the possibility that Kras mutations in human cancers may be less codon 12 restricted than is currently believed, and suggest that other K-ras codons ± including the ones identi®ed in our present study ± should be screened in tumors lacking codon 12 mutations.
As detailed in the Results section, certain types of transitions/transversions were far more common than others in . OH-treated DNA. For instance, although G/ C?A/T, T/A or C/G transitions/transversions at the ®rst or second position of codon 12 will all result in a mutant K-Ras protein that can eciently transform NIH3T3 cells (Seeburg et al., 1984) , we only detected one G/C?C/G in comparison to six G/C?T/A or ®ve G/C?A/T transitions/transversions at codon 12 in . OH-treated K-ras DNA. Likewise, we only detected G/C?T/A or G/C?A/T transitions/transversions in K-ras DNA containing 8 hydroxydeoxyguanosine incorporated into the ®rst or second position of codon 12. Interestingly, this same predominance of G/C?A/T or T/A, and paucity of G/C?C/G transitions/ transversions at codon 12 of K-ras has been noted in a review of several large studies of human lung and colon cancers (Bos, 1989) . While these results suggest that .
OH-induced DNA damage may preferentially cause certain types of transitions/transversions in Kras, a much larger number of . OH-induced K-ras mutations will need to be evaluated to de®nitively establish this possibility.
Previous studies, utilizing either single-stranded oligonucleotide templates in vitro or single-stranded DNA in bacteria or mammalian cells, have assessed the relative propensity of several . OH-modi®ed DNA bases, including 8 hydroxydeoxyguanosine (Kuchino et al., 1987; Shibutani et al., 1991; Wood et al., 1990; Moriya et al., 1991; Cheng et al., 1992; Moriya, 1993) , cytosine glycol (Hayes et al., 1988) , thymine glycol (Basu et al., 1989) , and 8 hydroxydeoxyadenosine (Guschlbauer et al., 1991) , to mispair with each of the four DNA bases. The spectrum of mutations observed in our .
OH-treated or 8 hydroxydeoxyguanosine-containing K-ras DNA is dierent than the spectrum one might predict from many of the aforementioned studies. Since the ®delity of replication of . OH-modi®ed DNA bases can vary greatly depending on the type of DNA polymerase employed, the surrounding primary DNA sequences, and/or whether the DNA template is single-or doublestranded (Kuchino et al., 1987; Shibutani et al., 1991; Basu et al., 1989; Kunkel and Alexander, 1986) ; the dierences between our results and these previous studies are not surprising. Indeed, these dierences underscore the importance of utilizing mammalian cells, double-stranded DNA, and genes that are relevant to human carcinogenesis as model systems for these types of studies. In addition, since we exclusively evaluated K-ras mutants which transformed NIH3T3 cells, and only certain mutations are transforming; the spectrum of mutations we detected was biased.
Although it could be questioned whether studies utilizing naked protooncogene cDNA plasmid constructs can accurately predict the spectrum of mutations that neutrophils/ . OH might cause in vivo (because of the absence of surrounding introns, chromosomal structure, histones and other cellular components); the similar codon 12 mutation pro®le between our .
OHtreated and 8 hydroxydeoxyguanosine-containing K-ras DNA (see Table 4 ), combined with the similar selectivity for K-ras over H-ras, preference for codons 12 and 61, and predominance of G/C?A/T or T/A transitions/transversions at codon 12 in our .
OHtreated K-ras DNA vs K-ras DNA isolated from human carcinomas, suggest that this system may be a very useful and predictive model of human carcinogenesis. Moreover, this model system oers the distinct advantage of allowing one to selectively assess the role of OH-mediated eects) in carcinogenesis. A similar model has been successfully employed in chemical carcinogenesis studies (Vousden et al., 1986) .
It will be important, in future studies, to utilize this system to generate a larger number of leukocyteactivated K-ras oncogenes, and compare their mutational spectra with the spectra of K-ras oncogenes isolated from leukocyte-treated epithelial cells or in¯ammation-associated human carcinomas. In addition, it will be important to further assess the mutational spectrum of 8 hydroxydeoxyguanosine, as well as other . OH-modi®ed G, C, A or T DNA bases, site-speci®cally incorporated into additional activatable K-ras codons. These combined studies could enable one to begin to delineate the speci®c characteristics of leukocyte-derived . OH-induced K-ras oncogene activation, and these characteristics might ultimately enable one to distinguish whether K-ras oncogene activation in human cancers resulted from leukocyte-derived . OHinduced DNA damage or some other carcinogen. A similar approach could be extended to additional oncogenes as well as tumor suppressor genes.
Materials and methods

Treatment of isolated K-ras 4B DNA with leukocytes
To determine if leukocytes can cause K-ras oncogene activation, normal human K-ras 4B protooncogene cDNA containing a 10 amino acid N-terminal leader (McCoy et al., 1984) , or normal human H-ras cDNA was cloned into the pZIP-Neo-SV(x)1 mammalian expression vector (Cepko et al., 1984) , and 10 mg of each ras construct was incubated with phorbol myristate acetate (PMA, 250 ng/ ml), human neutrophils (4610 6 /ml; isolated from normal donors according to previously described methods, Berkow et al., 1983) , and/or FeSO 4 /EDTA (10 mM/20 mM), in a ®nal volume of 100 ml of PBS for 1 h at 378C. Following incubation, DNA mixtures were centrifuged at 10 000 g for 5 s to pellet neutrophils; and supernatants were transferred to clean tubes. To determine if an enzymatic O 2 7 ⋅ and H 2 O 2 -generating system can cause K-ras oncogene activation, 10 mg of K-ras 4B plasmid DNA was incubated with purine (7H-Imidazo[4,5-d]pyrimidine, 2 mM) and xanthine oxidase (0.005 m/ml) (Schraufstatter et al., 1988) , in a ®nal volume of 100 ml of PBS for 1 h at 378C.
Incorporation of 8 hydroxydeoxyguanosine into codon 12 of ras cDNA
The name 8 hydroxydeoxyguanosine is used herein to emphasize its origin. It exists primarily as its 7,8-dihydro-8-oxodeoxyguanosine tautomer.
To assess the ability of 8 hydroxydeoxyguanosine to induce K-ras oncogene activation, we utilized the pGM 22 mammalian expression vector (Mitra et al., 1989) , which contains codons 1 ± 8 and codons 14 ± 189 of a nontransforming (codon 59=Ala) v-H-ras clone, separated by a 1.3 kb spacer fragment. pGM 22 was digested with BspMI to remove the spacer fragment, and a full-length ras gene, containing 8 hydroxydeoxyguanosine at codon 12, was reconstituted by ligating a synthetic double-stranded oligonucleotide (encoding codons 9 ± 13 of K-ras and containing 8 hydroxydeoxyguanosine substituted for deoxyguanosine at either the ®rst or second position of codon 12) into the BspMl site of PGM 22. 8-Hydroxydeoxyguanosine was incorporated into the synthetic oligonucleotide as previously described (Bodepudi et al., 1992) .
Transfection of NIH3T3 cells
1 mg of leukocyte-treated K-ras 4B or H-ras plasmid DNA, 1 mg of purine and xanthine oxidase-treated K-ras 4B plasmid DNA, or 400 ng of 8 hydroxydeoxyguanosinecontaining v-H-ras/K-ras 4B hybrid plasmid DNA was transfected, along with 20 mg of carrier calf thymus DNA, into NIH3T3 cells by calcium phosphate precipitation, according to previously described methods (Jackson et al., 1990) . Transfected dishes were maintained in Dulbecco's modi®ed Eagle's media/10% calf serum for 14 days, and subsequently analysed for the presence of morphologically transformed foci. Transformed foci were subcloned, and genomic DNA (20 mg) isolated from these primary transformants was individually transfected into NIH3T3 cells by calcium phosphate precipitation. (This second round of transfection prevents false positive transformants caused by multiple copies of ras plasmid DNA entering the same cell). Dishes were evaluated for the presence of secondary transformed foci 14 days following transfection.
Characterization of K-ras 4B mutations
Secondary ras-transformed foci were subcloned, and genomic DNA isolated from these subclones was amplified by the polymerase chain reaction (Saiki et al., 1985) , and directly sequenced (Higuchi and Ochman, 1989) . For leukocyte-and purine and xanthine oxidase-treated DNA, the entire K-ras 4B cDNA sequence was sequenced. For 8 hydroxydeoxyguanosine-containing DNA, sequencing was restricted to codons 8 ± 15.
Analysis of oncogenic K-Ras 4B protein expression
Subcloned secondary ras transformants were labeled overnight with 200 mCi/ml of 35 S Met/Cys (Trans 35 Slabel, ICN), and proteins contained in these cells were immunoprecipitated with anti-Ras antibody, Y13-259 (Furth et al., 1982) , and analysed by SDS ± PAGE and uorography, as previously described (Jackson et al., 1990) .
